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Abstract  
Takayasu arteritis (TA) is an idiopathic chronic granulomatous vasculitis that affects aorta, its 
main branches and occasionally pulmonary arteries. It is more common in Asian persons, 
affecting predominantly young women. Clinical presentation is nonspecific at the beginning of 
the disease, while in the ischemic disease’s stage it depends on the territories affected. We 
present the case of a 26-year-old woman who was diagnosed as having TA. Multiple vascular 
abnormalities of aorta and its branches and severely reduced left ventricular function were 
present at the time of diagnosis. Immunosuppressive treatment consisting of prednisone and 
azathyoprine along with conventional heart failure therapy significantly improved her cardiac 
function. 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
  
Takayasu arteritis (TA) is an idiopathic 
chronic granulomatous vasculitis that affects aorta, its 
main branches and occasionally pulmonary arteries 
[1]. TA is known worldwide with an estimated 
incidence of 1.2-2.6/million per year in the western 
population and is seen in all races, but the incidence 
is higher in Southeast Asia, Central and South 
America, and Africa [2]. Clinical presentation is 
nonspecific at the beginning of the disease with 
possible fever, malaise, anorexia, myalgia, joint pain. 
Months to years later, in the pulseless phase, 
symptoms such as limb claudication, abdominal pain, 
neurological manifestations or visual disturbances due 
to end-organ ischemia appear [3]. Clinically, 
decreased or absent peripheral pulses, arterial bruits 
and systemic arterial hypertension can be found [4]. 
Although the pattern of disease varies geographically, 
stenotic lesions that are found in 90% of patients 
predominate; aneurysms are reported in 
approxymately 25%, while cardiac involvement is 
considered to be rare [5]. 
The aim of this report was to present the case 
of a 26-year-old woman who was diagnosed as 
having TA. 
 
 
Case report 
 
A 26-year-old woman was admitted at our 
institution in October 2012. She was complaining of 
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malaise, shortness of breath, paroxysmal chest pain, 
subfebrile temperature, night sweats and weight loss 
of 10 kg over a period of one year. Her symptoms 
progressed over the course of two years. On 
examination, the patient was pale, without significant 
lymphadenopathy and detectable joints swelling. 
Chest auscultation revealed a loud pansystolic 
murmur throughout the precordium. Bruits were 
evident over both common carotid arteries, more so 
over the right. A significant clinical finding included a 
diminished left radial pulse compared to the right. 
Blood pressure measured on both arms was slightly 
elevated (140/90 mm Hg), but was not significantly 
asymmetric. Routine laboratory results revealed a 
raised erythrocyte sedimentation rate (ESR) and C-
reactive protein (CRP) at 105 mm/h and 103 mg/L, 
respectively.  
 
Figure 1: CT angiography shows axial view of the aorta; concentric 
mural thickening and aneurismatic dilatation of the ascending aorta 
was found 
 
Immunological tests including antinuclear, 
anti-neutrophil cytoplasmic, anti citric citullinated 
peptide, anticardiolipin, and anti beta 2 glycoprotein 
antibodies, rheumatoid factor, complement fractions 
and cryoglobulins were all negative. Protein 
electophoresis revealed an elevated gamma globuline 
fraction (28.8% of total proteins) and immunoglobuline 
G (21 g/l) with a normal fraction of IgG4 subclass. 
Sputum studies for acid fast bacilli and PPD test for 
tuberculosis were negative. Treponema Pallidum 
Haemagglutination assay was negative. No positive 
laboratory markers for sarcoidosis were found. A 
transthoracic heart Doppler ultrasound revealed a 
medium grade aortic regurgitation and left ventricular 
enlargement with a severe impairement of systolic 
function with ejection fraction of 30% (EF of 55 
percent or higher is considered normal). A poorly 
contractile heart with features typical to dilatative 
cardyomyopathy was demonstrated; a larger 
ascending aortic diameter and a thickened aortic wall 
up to 8 mm in particular places, initially suspected to 
aortic dissection were seen (wall thickness up to 4 
mm is regarded normal). Carotid Dopplers revealed 
high-grade stenoses at the bifurcation of both 
common carotid artery, significant wall thickening in 
both subclavian arteries, with a severely diminished 
flow on the left. A computed tomography arteriogram 
revealed multiple stenosis and dilatations of the aortic 
arch, ascending and descending aorta with features of 
arteritis in the wall. The most prominent dilatation, with 
a transversal diameter of 50 mm, was seen at the 
ascending aorta (Figure 1) and the most striking 
stenosis was observed in the middle of the 
descending aorta (Figure 2). Most of the main 
branches of aorta appeared irregularly shaped, but 
narrowing of the renal arteries was not present. 
 
Figure 2: CT angiography shows sagital view; stenosis of the 
thoracic aorta up to 17,2mm was seen 
 
The patient fulfilled five of six necessary 
American College of Rheumatology (ACR) 
classification criteria for TA and the treatment by 
prednisolone of 1 mg per kilogram per day was 
started. After two weeks of therapy, an improvement 
of inflammatory signs was noticed. Her constitutional 
symptoms disappeared with the resolution of 
inflammatory markers. Additionally, therapy consisting 
of enalaprile, amlodipine, hydrochlorthiazide, 
spironolactone and aspirin was suggested. Few 
weeks later, Azathioprine 100mg per day was 
administered along with gradually reduction of 
prednisone. Median levels of ESR, CRP, diminished 
to 18 mm/h and 3.0 mg/l, respectively. On a follow up 
visit, six months later, all laboratory tests were within 
normal range. Her cardiac function was significantly 
improved, and an estimated EF of 50% was 
measured. 
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Discussion 
 
Takayasu’s arteritis is a systemic 
inflammatory disease of unknown etiology [1]. It is 
more common in Asian persons, affecting 
predominantly young women [6]. TA is a panarteritis 
mediated by T lymphocyte, monocyte and 
macrophage that infiltrate arterial wall, leading to 
marked intimal myofibroblast proliferation and fibrosis 
of the media and adventitia [7]. The disease has a 
biphasic course. The early systemic or ‘pre-pulseless’ 
phase is characterized by active inflammation and 
nonspecific signs and symptoms, including fever, 
malaise, anorexia, weight loss, carotidynia, myalgia 
and arthralgia [3]. During the course of the disease, 
manifestations such as hypertension, bruits, 
headaches, postural dizziness, and syncope may 
appear. Clinical presentation in the late or ‘pulseless’ 
phase is largely dependent upon the site and grade of 
arterial lesion [8]. In 1990, the ACR proposed 
classification criteria for diagnosis of TA: age of 
disease onset < 40 years, claudication of extremities, 
decreased brachial artery pulse, blood pressure 
difference > 10 mmHg, bruit over subclavian arteries 
or aorta, arteriogram abnormality. The presence of 3 
or more of these 6 criteria demonstrated a sensitivity 
of 90.5% and a specificity of 97.8% in diagnosis of TA 
[9]. Moreover, although diagnostic criteria exist, 
patients presenting with early pre–stenotic disease 
may not fulfil them [10]. For that reason, the delay in 
diagnosis from initial manifestation of the disease can 
be 2–11 years in adults and sometimes longer in 
children [11]. This is complicated by the lack of 
specific laboratory markers including autoantibodies 
[12]. Some patients develop cardiac abnormalities, 
that are, generally regarded, consequence of 
hypertension, pulmonary vascular involvement, 
coronary artery disease and aortic regurgitation. 
However, in some cases, the left ventricule 
dysfunction was documented without associated 
hypertension, valvular lesion or coronary artery 
disease [13]. Talwar et al reported that combined 
therapy of prednisolone and cyclophosphamide over 
12 weeks improved not only clinical and 
hemodynamic state, but also myocardial morphology 
of patients with Takaysu myocarditis [14]. These 
findings strongly suggest that immunological 
processes play a significant role in TA related 
myocarditis [13]. According to the recent study of 
Yang et al, hypertension, major complications, and a 
progressive disease course are statistically significant 
predictors of 5-years survival [15]. 
Aortic lesions are often associated with 
aortitis in several divergent etiologies such as 
connective tissue diseases, infective and IgG4-related 
sclerosing aortitis [16, 17]. 
The rarity of TA and the heterogeneous 
nature of the possible clinical manifestations often 
lead to a late diagnosis and delayed treatment. 
Nazareth et al.,  tried to facilitate this suggesting ‘red 
flags symptoms’ that should alert the physician to the 
possibility of TA. In their cohort of 68 patients, 91% 
displayed one or more red flag symptoms: carotidynia, 
angina, limb claudication, absent or weak peripheral 
pulses, hypertension discrepant blood pressure in the 
upper limbs (> 10 mmHg), arterial bruits, aortic 
regurgitation or non explained acute-phase response, 
such as elevated ESR or CRP [4]. 
The mainstay in the treatment of TA is 
glucocorticosteroids (gks) for induction of remission 
and for maintenance in low doses up to 1 to 2 years. 
However, the risk of relapse following gks withdrawal 
is high and gks-sparing drugs including methotrexate 
or azathyoprine are often recommended [18]. Pulsed 
intravenous cyclophosphamide is reserved for those 
with life-threatening disease or failing to respond to 
first-line treatments [19]. Recent reports suggest that 
patient refractory to conventional therapy might 
respond to tumor-necrosis factor or interleukin 6 
blockers [20]. Treatment of hypertension and 
prevention of thrombosis are also important aspects of 
therapy [21]. 
In our case, gks administration, in conjunction 
with an additional immunosuppressant and 
conventional heart failure therapy dramatically 
restored left ventricular systolic function. These 
findings suggest that cytotoxic mechanisms similar to 
those in the walls of vessel affected, may also 
contribute to cardiac involvement in certain patients 
with Takayasu arteritis [13]. Surgery may be needed 
in patients with critical renal artery stenoses, limb 
claudication limiting the daily activities, stenosis of 
three or more cerebral vessels and moderate aortic 
regurgitation [22].  
Assessing disease activity in TA is 
challenging as there is frequently a lack of clinical and 
investigational correlation. New onset or worsening of 
two or more of the criteria of TA are indicative of 
disease exacerbation [6], though angiographic 
disease progression and histological progression can 
be seen even during an inactive phase of the disease. 
A similar situation is faced with the assessment of 
laboratory markers such as ESR and several other 
acute phase reactants. Recent investigations have 
focused on identification of novel and sensitive 
biomarkers of the disease activity such as pentraxin-3 
[23] and imaging techniques such as 
18
F-FDG 
PET/CT [24].  
In conclusion, we emphasize the importance 
of the early diagnosis of TA, which can be difficult due 
to initial nonspecific symptoms and clinical 
presentation. The case presented above demonstrate 
the serious consequences associated with a delayed 
diagnosis, and propose that this might be prevented 
by increased clinical awareness of TA and early use 
of non-invasive imaging such as 
18
F-FDG PET/CT. 
Early treatment with gks and cytotoxic agents is 
important to avoid rapid progression of the vascular 
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lesions and may prevent irreversible cardiovascular 
complications.  
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